Crinetics Pharmaceuticals (CRNX) EPS (Basic) (2017 - 2026)

Crinetics Pharmaceuticals' EPS (Basic) history runs 10 years deep, the most recent figure standing at -$2.39 for Q1 2026.

• In Q1 2026, EPS (Basic) fell 330.37% year-over-year to -$2.39; the TTM figure through Mar 2026 stood at -$3.71 (down 2677.55% YoY), while the FY2025 annual figure was -$4.95, down 34.14% from the prior year.
• EPS (Basic) for Q1 2026 stood at -$2.39, down from -$1.3 in the prior quarter.
• The five-year high for EPS (Basic) was $1.23 in Q2 2025, with the low at -$6.25 in Q4 2023.
• The 5-year median for EPS (Basic) is $0.81 (2022), against an average of -$0.19.
• The sharpest annual moves came in 2022 and 2023: EPS (Basic) jumped 118.03% in 2022, then tumbled 821.76% in 2023.
• Crinetics Pharmaceuticals' EPS (Basic) stood at $0.87 in 2022, then sank by 821.76% to -$6.25 in 2023, then soared by 84.03% to -$1.0 in 2024, then plunged by 30.69% to -$1.3 in 2025, then plunged by 83.66% to -$2.39 in 2026.
• Business Quant data shows CRNX's EPS (Basic) at -$2.39 in Q1 2026, -$1.3 in Q4 2025, and -$1.38 in Q3 2025.